Pharmaceutical

Multiple Paths to Commercial Success

LIQUID STRUCTURE CBD – NEUROPATHIC PAIN

 

Phase 1 (safety) underway – Phase 2A (proof of concept) in process

LIQUID STRUCTURE CBD – OPIOID REPLACEMENT & WITHDRAWAL

 

Phase 1 (safety) underway – Phase 2A (proof of concept) in concert or swapped with neuropathic pain

Helping resolve the opioid – a candidate for accelerated approval

LIQUID STRUCTURE CBD – RETT SYNDROME, CBD AS AN ORPHAN DRUG

 

Streamlined FDA approval – reduced requirements & shortened time to market

Partnerships with Rett Syndrome agencies & medical centers

Considerable media attention with success

PROVIDE TO PARTIES PURSUING CBD FOR OTHER MEDICAL CONDITIONS

 

Liquid Structure CBD provided to those pursuing additional maladies

Allows the bypass of Phase 1 – a saving of time (years) and money ($ millions)

Partnerships or royalties with/from the other parties

ANANDA’s own progress towards regulatory approval will grow this opportunity

First Target Neuropathic Pain & Opioid Replacement

SEVERE, CHRONIC PAIN 33M AMERICAN PATIENTS

Global 675M, China 100M, Europe 76M, Latin America 61M, Japan 13M, Canada − 3M

ANNUAL US TREATMENT COSTS – $400B

NEUROPATHIC PAIN TYPICALLY TREATED WITH OPIOIDS

  • Main driver of US overdose deaths 48,000 in 2018
  • Opioid crisis costing more than $500B per year in the US
  • Huge demand for non addictive alternative therapies
  • Almost no opioid use in China, tremendous need there for pain relieving alternatives

LIQUID STRUCTURE CBD REPLACING OPIOIDS – CASE STUDY SUCCESS

  • Stage 4 cancer neuropathic pain so severe that even the most potent and addictive opioid, fentanyl, often does not work
  • Pain successfully controlled with Liquid Structure CBD
  • 75% overall reduction in opioid use with Liquid Structure CBD
  • 25% totally replaced opioids for pain relief with Liquid Structure CBD
  • Liquid Structure CBD reduces opioid withdrawal urges

Fewer hurdles to FDA approval for neuropathic pain opioid use reduction than with conditions like diabetes, inflammatory bowel disease or arthritis

 

As a safe, non addictive alternative to opioids, accelerated FDA approval for Liquid Structure CBD a real option

  1. LEADER IN SEEKING REGULATORY APPROVAL OF CBD FOR A MAJOR MEDICAL CONDITION
  2. ENGAGED IN FDA COMPLIANT HUMAN CLINICAL TRIALS TO TREAT NEUROPATHIC PAIN
  3. CASE STUDY RESULTS POINTING TO THE LIKELIHOOD OF FDA APPROVAL SU CCESS

PATH TO PHARMACEUTICAL COMMERCIALIZATION